Interstitial lung diseases in a lung cancer screening trial

N. Sverzellati, L. Guerci, G. Randi, E. Calabrò, C. La Vecchia, A. Marchianò, A. Pesci, M. Zompatori, U. Pastorino

Research output: Contribution to journalArticlepeer-review

Abstract

We assessed the prevalence of interstitial lung disease (ILD) in a cohort of smokers included in a lung cancer screening trial. Two observers independently reviewed, for the presence of findings consistent with ILD, the computed tomography (CT) examinations of 692 heavy smokers recruited by the Multicentric Italian Lung Detection (MILD) trial. Four CT patterns were considered: usual interstitial pneumonia (UIP), other chronic interstitial pneumonia (OCIP), respiratory bronchiolitis (RB) and indeterminate. Subsequently, the evolution of ILD in those subjects who had undergone a repeat CT examination after 3 yrs was assessed. The UIP pattern and the OCIP pattern were identified in two (0.3%) out of 692 and 26 (3.8%) out of 692 patients, respectively; 109 (15.7%) out of 692 patients showed CT abnormalities consistent with RB, while an indeterminate CT pattern was reported in 21 out of 692 (3%) patients. Age, male sex and current smoking status were factors associated with the presence of OCIP and UIP (combined) pattern, although the relationship did not attain statistical significance. A progression of the disease was observed in three (25%) out of 12 subjects with OCIP who underwent repeat CT after 3 yrs. Thin-section CT features of ILD, probably representing smoking-related ILD, are not uncommon in a lung cancer screening population and should not be overlooked. Copyright

Original languageEnglish
Pages (from-to)392-400
Number of pages9
JournalEuropean Respiratory Journal
Volume38
Issue number2
DOIs
Publication statusPublished - Aug 1 2011

Keywords

  • Cigarette smoking
  • Computed tomography
  • Interstitial lung disease
  • Lung cancer
  • Screening

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Interstitial lung diseases in a lung cancer screening trial'. Together they form a unique fingerprint.

Cite this